undamentalytics Newsletter
Sign in

Cbdmd, Inc. key statistics and ratios

In fiscal 2025, Cbdmd, Inc. had return on equity of -44.4% and a net margin of -10.6%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Sept 20162017Sept 20172018Sept 20182019Sept 20192020Sept 20202021Sept 20212022Sept 20222023Sept 20232024Sept 20242025Sept 2025LTMJun 2026
Net margin−191.8%−31.0%13.7%−217.1%30.1%−52.6%−198.0%−95.0%−19.0%−10.6%−13.8%
Return on equity—−60.6%0.7%−199.0%21.6%−25.7%−104.2%−113.4%−67.3%−44.4%−37.4%
Return on assets−240.0%−31.9%0.6%−93.8%12.3%−19.8%−84.6%−80.5%−27.6%−19.4%−24.5%
Effective tax rate————11.9%——————
Dividends ÷ net income————2.9%——————

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $13m
Short-term assets $8mLonger-term assets $5m
What it owes, and who funded it · $13m
Short-term liabilities $3mLonger-term liabilities $2mShareholders' equity $8m
  • Short-term assets cover short-term liabilities $8m of assets due within a year against $3m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $8m short-term assets against $2m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Cbdmd, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

30 /100

Weak moat

How hard Cbdmd's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -23.0% of total assets over 9 years.

  • Pricing power 18 / 20

    Gross margin has been a median 62.3%, moving by 3.8 percentage points (standard deviation) across 9 years.

  • Durability 10 / 20

    Operating margin has been a median -46.0%; its worst year was -188.3%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 9 years, at a median -24.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (35 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: AXIL vs YCBDNHTC vs YCBDFTLF vs YCBDUG vs YCBD

More: Personal Care Products stocks compared, Consumer Staples sector, rankings of US companies

Figures from Cbdmd, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cbdmd, Inc.